Big news for acromegaly at Crinetics

From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly patient. If approved, Paltusotine will offer the first nonpeptide one-time a day oral drug for the treatment of acromegaly. Dr. Alan Krasner, Crinetics Chief Medical Officer, says their goals are for this once-daily oral option to help control hormone levels while relieving the burden of pain of currently available therapies. Listen to Dr. Krasner in this PWN podcast recorded in early 2020 as he describes their drug development efforts.

Crinetics will be enrolling 52 patients for this initial one of two studies needed to assess the safety and efficacy of the drug and move forward to make it available to patients around the world.  Specifically, the study called Pathfndr-1 needs acromegaly patients who are biochemically controlled with octreotide or lanreotide.

I asked Dr. Blevins for his take. “Participation in a clinical trial,” he said, “often enables a patient to undergo treatment for a rare disease before the particular therapy has been approved by the US Food and Drug Administration (FDA) or other governing bodies. Not all investigations on drugs and therapies prove to be effective. Thus, there is some “risk” of delaying appropriate or effective treatment. The risks and benefits of participating in a clinical trial are different for everyone. They must be weighed individually when considering enrollment in a clinical trial. Many patients participate in clinical trials to achieve satisfaction as a result of their contribution to the understanding of diseases and treatments and the sense that they are giving something to society as a whole”

If you are thinking about participating, we recommend you learn about the trial here, talk to your doctors and the clinicians in the study, and learn as much as you can about trials in general. The National Institutes for Health (NIH) is a great source to learn about the ins and outs of clinical trials. You may want to read about the NIH resources here. And to see if you can participate in the pathfinder-1 trial, this link will take you to a dedicated page for the study. All your questions, who to contact, and what to do next should be answered here. In addition, PWN produced a series of six podcasts with Crinetics scientists and medical professionals about the steps necessary to go from a molecule to actual medication that will give you a real insider’s view of this complicated but rewarding process.

This downloadable “Pathfndr-1” brochure answers the most common questions.

Click here for more information



© 2021 – 2022, Pituitary World News. All rights reserved.